Do thiazolidinediones cause heart failure? A critical review

被引：27

作者：

Tang, WHW ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Sect Heart Failure & Cardiac Transplantat, Cleveland, OH 44195 USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2006年 / 73卷 / 04期

关键词：

D O I：

10.3949/ccjm.73.4.390

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Concern has been raised about whether the fluid retention caused by thiazolidinediones (TZDs, ie, rosiglitazone and pioglitazone) can cause or exacerbate congestive heart failure. Although fluid retention is a worrisome side effect of TZDs, current evidence does not link fluid retention caused by TZDs with worsening heart function. TZDs have many benefits for patients with diabetes and can even be used cautiously in patients with mild heart failure, with careful monitoring of. volume status.

引用

页码：390 / 397

页数：8

共 43 条

[1] Heart failure - The frequent, forgotten, and often fatal complication of diabetes [J].

Bell, DSH .

DIABETES CARE, 2003, 26 (08) :2433-2441

[2] Unilateral edema due to a thiazolidinedione [J].

Bell, DSH .

DIABETES CARE, 2003, 26 (09) :2700-2700

[3] Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator [J].

Berger, JP ;

Petro, AE ;

Macnaul, KL ;

Kelly, LJ ;

Zhang, BB ;

Richards, K ;

Elbrecht, A ;

Johnson, BA ;

Zhou, GC ;

Doebber, TW ;

Biswas, C ;

Parikh, M ;

Sharma, N ;

Tanen, MR ;

Thompson, GM ;

Ventre, J ;

Adams, AD ;

Mosley, R ;

Surwit, RS ;

Moller, DE .

MOLECULAR ENDOCRINOLOGY, 2003, 17 (04) :662-676

[4] Thiazolidinedione-induced congestive heart failure [J].

Cheng, AYY ;

Fantus, IG .

ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) :817-820

[5]

Dargie H, 2005, J AM COLL CARDIOL, V45, p186A

[6]

Dargle H, 2005, J AM COLL CARDIOL, V45, p139A

[7] Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study [J].

Delea, TE ;

Edelsberg, JS ;

Hagiwara, M ;

Oster, G ;

Phillips, LS .

DIABETES CARE, 2003, 26 (11) :2983-2989

[8] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[9] Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes [J].

Emoto, M ;

Anno, T ;

Sato, Y ;

Tanabe, K ;

Okuya, S ;

Tanizawa, Y ;

Matsutani, A ;

Oka, Y .

DIABETES, 2001, 50 (05) :1166-1170

[10]

*GLAX SMITH KLIN, 2000, AV PACK INS

← 1 2 3 4 5 →